研究文章
构象建模和分子对接一些活性化合物的分析结核分枝杆菌受体(Mtb CYP121)
表10
亲和力的1、2、4-Triazole衍生品结核分枝杆菌目标(Mtb CYP121)。
|
| 配位体 |
目标 |
亲和力(BA) 千卡每摩尔 |
|
| 1 |
Mtb CYP121 |
−7.3 |
| 2 |
Mtb CYP121 |
−7.8 |
| 3 |
Mtb CYP121 |
−8.5 |
| 4 |
Mtb CYP121 |
−9.1 |
| 5 |
Mtb CYP121 |
−9.6 |
| 6 |
Mtb CYP121 |
−9.8 |
| 7 |
Mtb CYP121 |
−10.3 |
| 8 |
Mtb CYP121 |
−14.6 |
| 9 |
Mtb CYP121 |
−9.6 |
| 10 |
Mtb CYP121 |
−9.6 |
| 12 |
Mtb CYP121 |
−9.2 |
| 13 |
Mtb CYP121 |
−11.2 |
| 14 |
Mtb CYP121 |
−11.2 |
| 15 |
Mtb CYP121 |
−5.1 |
| 11 |
Mtb CYP121 |
−9.9 |
| 16 |
Mtb CYP121 |
−5.3 |
| 17 |
Mtb CYP121 |
−6.1 |
| 18 |
Mtb CYP121 |
−7.9 |
| 19 |
Mtb CYP121 |
−7 |
| 20. |
Mtb CYP121 |
−7.8 |
| 21 |
Mtb CYP121 |
−5.5 |
| 22 |
Mtb CYP121 |
−5.7 |
| 23 |
Mtb CYP121 |
−5.5 |
| 24 |
Mtb CYP121 |
−6.9 |
| 25 |
Mtb CYP121 |
−6.6 |
| 26 |
Mtb CYP121 |
−6.7 |
| 27 |
Mtb CYP121 |
−5.4 |
| 28 |
Mtb CYP121 |
−5.1 |
| 29日 |
Mtb CYP121 |
−5.4 |
| 30. |
Mtb CYP121 |
−7.5 |
| 31日 |
Mtb CYP121 |
−7.3 |
| 32 |
Mtb CYP121 |
−6.6 |
| 33 |
Mtb CYP121 |
−5.6 |
| 34 |
Mtb CYP121 |
−6 |
| 35 |
Mtb CYP121 |
−6.3 |
| 36 |
Mtb CYP121 |
−7.8 |
| 37 |
Mtb CYP121 |
−7.8 |
| 38 |
Mtb CYP121 |
−8.4 |
| 39 |
Mtb CYP121 |
−5.7 |
| 40 |
Mtb CYP121 |
−6.3 |
| 41 |
Mtb CYP121 |
−6.3 |
| 42 |
Mtb CYP121 |
−5.9 |
| 43 |
Mtb CYP121 |
−5.6 |
| 44 |
Mtb CYP121 |
−5.5 |
| 45 |
Mtb CYP121 |
−6.2 |
| 46 |
Mtb CYP121 |
−5.7 |
| 47 |
Mtb CYP121 |
−5.9 |
| 48 |
Mtb CYP121 |
−5.7 |
| 49 |
Mtb CYP121 |
−5.2 |
| 50 |
Mtb CYP121 |
−7.8 |
|
|